

31<sup>st</sup> October 2022

Ajanta House Charkop, Kandivli West, Mumbai 400 067 India T +91 22 6606 1000
F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

BSE LIMITED	National Stock Exchange of India,
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 <sup>th</sup> Floor, Plot no.
Dalal Street,	C/1, G Block, Bandra Kurla Complex,
Mumbai – 400001	Bandra (East), Mumbai – 400 051
Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ

## **Ref.:** Intimation under Regulations 29(1)(e) of the Listing Regulations

## Subject: Notice of the meeting of Board of Directors to consider dividend on equity shares of the company

Dear Sirs/Madam,

This is with reference to our letter dated 21<sup>st</sup> October 2022, informing you about the Board meeting scheduled on Thursday, 3<sup>rd</sup> November 2022 to *inter-alia* consider and take on record the unaudited financial results for the second quarter and half year ended 30<sup>th</sup> September 2022.

Pursuant to Regulation 29(1)(e) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider proposal for:

- a. declaration of interim dividend, if any, for the financial year ending 31st March 2023; and
- b. fixation of Monday, 14<sup>th</sup> November, 2022 as the Record Date for the payment of interim dividend, if declared.

You are requested to please take a note of the same and disseminate to all concerned.

Thanking you,

Yours faithfully,

**Gaurang Shah** VP – Legal & Company Secretary